

Translational Research in Veterinary Oncology: From Bench Discoveries to Clinical Applications for Enhanced Cancer Care in Animals

Dr Anand Gudur , Incharge, Oncology, Faculty of Medical Sciences, anandgudur@gmail.com

Dr. Mrs V. M. Thorat, Professor & Head, Dept. of Pharmacology, Faculty of Medical Sciences, vmthorat@yahoo.co.in

Dr. Mrs A. R. Shinde, Professor Dept. of Pharmacology, Faculty of Medical Sciences, anjaliravindrashinde@gmail.com

Krishna Vishwa Vidyapeeth “Deemed to be University”, Taluka-Karad, Dist-Satara, Pin-415 539, Maharashtra, India

Abstract: The field of veterinary oncology stands at a pivotal juncture, where translational research plays a crucial role in bridging the gap between bench discoveries and clinical applications. With cancer being a leading cause of morbidity and mortality in companion animals, the integration of cutting-edge scientific findings into clinical practice holds immense promise for advancing cancer care and improving outcomes. At the forefront of this endeavor lies a multidisciplinary approach that leverages insights from molecular biology, immunology, genetics, and pharmacology. Through a synergistic collaboration between basic scientists, clinicians, and veterinary oncologists, novel therapeutic strategies are being developed and refined, tailored to the unique biological characteristics of various tumor types encountered in veterinary patients. Key areas of focus in translational research include elucidating the molecular mechanisms underlying cancer initiation, progression, and metastasis, as well as identifying biomarkers for early detection, prognostication, and treatment response assessment. By unraveling the intricate interplay between tumor cells and the host microenvironment, researchers aim to devise targeted therapies that disrupt oncogenic signaling pathways while sparing normal tissues. Immunotherapy represents a paradigm shift in cancer treatment, with recent advances in veterinary oncology mirroring those in human medicine. From checkpoint inhibitors to chimeric antigen receptor (CAR) T-cell therapy, immunomodulatory approaches are revolutionizing the management of certain malignancies, offering new hope for patients previously deemed incurable.

Keywords: Veterinary Oncology, Translational Research, Cancer Care, Clinical Applications, Animal Health

I. Introduction

Veterinary oncology stands as a critical field within veterinary medicine, dedicated to understanding and treating cancer in animals. With cancer being a leading cause of morbidity and mortality in companion animals, the need for innovative approaches to cancer care has never been more pressing. Translational research serves as the conduit through which groundbreaking discoveries made at the bench are translated into tangible clinical applications, ultimately enhancing cancer care for animals. This introduction sets the stage for exploring the journey from bench discoveries to clinical advancements in veterinary oncology. The

foundation of translational research in veterinary oncology lies in its multidisciplinary nature, drawing upon insights from various scientific disciplines such as molecular biology, immunology, genetics, and pharmacology [1]. By synthesizing knowledge from these diverse fields, researchers aim to unravel the complex mechanisms underlying cancer development, progression, and metastasis in animals. This comprehensive understanding serves as the cornerstone for devising targeted therapeutic interventions tailored to the unique biological characteristics of different tumor types encountered in veterinary patients. At the heart of translational research in veterinary oncology is the collaboration between basic scientists, clinicians, and veterinary oncologists. This collaborative effort facilitates the seamless integration of laboratory discoveries into clinical practice, ensuring that cutting-edge treatments and diagnostic modalities are rapidly translated from bench to bedside [2]. By fostering a synergistic relationship between researchers and practitioners, translational research accelerates the pace of innovation in veterinary oncology, ultimately benefiting animal patients and their caregivers.




Figure 1: Process of translational research in veterinary oncology, from bench discoveries

One of the primary objectives of translational research in veterinary oncology is to identify biomarkers that can aid in early cancer detection, prognostication, and treatment response assessment. By elucidating the molecular signatures associated with different tumor types, researchers can develop sensitive and specific diagnostic tests that enable early intervention and improve patient outcomes. Moreover, biomarker discovery facilitates the development of personalized treatment strategies, allowing veterinarians to tailor therapies to the individual needs of each animal patient. Immunotherapy has emerged as a game-changing approach in cancer treatment, both in human and veterinary medicine [3]. By harnessing the power of the immune system to recognize and eliminate cancer cells, immunotherapy offers new avenues for combating a wide range of malignancies in animals. From checkpoint inhibitors that unleash the immune system's ability to target tumors to chimeric antigen receptor (CAR) T-cell therapy that engineers immune cells to recognize and destroy cancer cells, immunomodulatory approaches are revolutionizing cancer care in veterinary oncology.

II. Background

Veterinary oncology encompasses the diagnosis, treatment, and management of cancer in animals, ranging from companion pets to livestock and wildlife species. Cancer represents a significant health concern across diverse animal populations, with incidence rates varying by species, breed, age, and environmental factors. Similar to human medicine, the field of veterinary oncology has witnessed remarkable advancements in recent decades, driven by a deeper understanding of cancer biology, innovative treatment modalities, and a growing emphasis on translational research. Historically, veterinary oncology has primarily relied on surgical excision, radiation therapy, and conventional chemotherapy to combat cancer in animals [4]. While these treatment modalities remain cornerstone approaches, ongoing research efforts have expanded the therapeutic armamentarium to include targeted therapies, immunotherapy, and personalized medicine. This evolution reflects a shift towards precision oncology, wherein treatment decisions are informed by the molecular characteristics of individual tumors and the unique biology of each patient. The advent of translational research has revolutionized the landscape of veterinary oncology by facilitating the translation of scientific discoveries from the laboratory to the clinic [5]. Translational research encompasses a continuum of investigation, spanning basic science research aimed at elucidating fundamental biological processes underlying cancer, to clinical trials evaluating novel therapeutic interventions in animal patients. This interdisciplinary approach fosters collaboration between researchers, clinicians, and veterinary oncologists, bridging the gap between bench discoveries and clinical applications. Central to translational research in veterinary oncology is the concept of comparative oncology, which recognizes the striking similarities between cancer in humans and animals. Shared features include common tumor types, genetic mutations, molecular pathways, and responses to treatment.

Table 1: Summary of Related Work

Application	Approach	Challenges	Impact
Diagnosis and Treatment Selection	Utilizing naturally occurring cancers in animals to study similarities with human cancers	Variability in tumor biology between species	Facilitates the identification of effective treatments for both human and veterinary patients
Personalized Medicine [6]	Analyzing tumor DNA to identify genetic mutations and potential therapeutic targets	Cost and complexity of sequencing technologies	Enables tailored treatment regimens based on individual tumor characteristics
Immunomodulation	Harnessing the immune system to target and destroy cancer cells	Immune-related adverse effects	Offers new treatment options for previously incurable cancers

Precision Oncology	Inhibiting specific molecular targets involved in cancer growth and progression	Development of resistance mechanisms	Provides more effective and less toxic alternatives to traditional chemotherapy
Therapeutic Development	Evaluating the efficacy and safety of novel treatments in animal models	Limited predictive value for clinical outcomes	Validates experimental interventions before clinical trials
Treatment Evaluation	Testing experimental therapies in human or animal subjects to assess efficacy and safety	Recruitment and retention of participants	Determines the efficacy and safety of new treatments in real-world settings
Early Detection and Prognostication	Identifying molecular markers associated with cancer development and progression	Validation and standardization of biomarkers	Facilitates early diagnosis, prognostication, and treatment response assessment
Disease Staging and Monitoring [7]	Utilizing imaging modalities such as CT, MRI, and PET to detect and monitor cancer	Cost and availability of equipment	Enables accurate staging and monitoring of tumor progression
Disease Characterization	Examining tissue samples to identify specific molecular alterations associated with cancer	Interpretation of complex molecular data	Provides insights into tumor biology and informs treatment decisions
Risk Assessment and Prevention	Investigating environmental and genetic factors contributing to cancer development	Data collection and analysis challenges	Guides preventive strategies and public health interventions
Symptom Management	Providing palliative care and supportive therapies to improve quality of life in cancer patients	Access to supportive care resources	Mitigates treatment-related side effects and enhances patient comfort
Cost-Effectiveness Analysis	Evaluating the economic impact of cancer treatments and interventions	Data availability and accuracy	Informs healthcare resource allocation decisions and policy-making

III. Bench Discoveries in Veterinary Oncology

A. Advancements in cancer biology and treatment modalities

Recent advancements in cancer biology have significantly enriched our understanding of the molecular mechanisms driving tumorigenesis and tumor progression in veterinary oncology. Through cutting-edge research, scientists have elucidated intricate signaling pathways, genetic mutations, and dysregulated cellular processes underlying various tumor types in animals [8]. These discoveries have unveiled novel therapeutic targets and paved the way for the development of innovative treatment modalities tailored to the unique biology of each tumor. One notable area of progress lies in the field of targeted therapy, wherein drugs are designed to specifically inhibit molecular targets that drive cancer growth and survival. By exploiting vulnerabilities within cancer cells, targeted therapies offer the potential for increased efficacy and reduced toxicity compared to traditional chemotherapy. In veterinary oncology, targeted agents have shown promise in treating specific tumor types, such as mast cell tumors, melanomas, and sarcomas, among others. Moreover, advancements in immunotherapy have revolutionized cancer treatment paradigms, harnessing the power of the immune system to recognize and eradicate tumor cells [9]. Immunomodulatory approaches, including checkpoint inhibitors, adoptive cell therapies, and cancer vaccines, have demonstrated remarkable success in certain malignancies, both in animals and humans. By enhancing the host immune response against cancer, immunotherapy holds the potential to achieve durable remissions and improve long-term survival outcomes in veterinary patients.

B. Key discoveries in veterinary oncology research

In recent years, veterinary oncology research has yielded several key discoveries that have significantly advanced our understanding and treatment of cancer in animals. One notable breakthrough is the identification of genetic mutations and molecular alterations driving tumorigenesis in various animal species. Through genomic sequencing and molecular profiling studies, researchers have uncovered key oncogenic drivers and tumor suppressor genes implicated in different cancer types, providing crucial insights into the underlying biology of these diseases [10]. Furthermore, comparative oncology studies have revealed striking similarities between certain cancers in humans and animals, highlighting the value of studying naturally occurring tumors in veterinary patients. For example, canine osteosarcoma shares many similarities with human osteosarcoma, including genomic alterations, tumor microenvironment characteristics, and response to therapy. These parallels not only inform our understanding of cancer pathogenesis but also offer valuable translational opportunities for developing new treatment strategies that benefit both animal and human patients. Another significant discovery in veterinary oncology research is the role of the tumor microenvironment in tumor progression and treatment response [11]. Studies have elucidated the complex interactions between cancer cells, immune cells, stromal cells, and extracellular matrix components within the tumor microenvironment, shaping the tumor's behavior and therapeutic vulnerabilities. Targeting these interactions through immunotherapy, tumor microenvironment

modulation, and combination therapies has emerged as a promising approach to enhance treatment efficacy and overcome resistance in veterinary cancer patients.

IV. Preclinical Studies and Translational Models

A. Role of preclinical studies in validating bench discoveries

Preclinical studies play a vital role in the translation of bench discoveries into clinically relevant applications in veterinary oncology. These studies serve as a crucial intermediary step between initial laboratory findings and human or animal trials, providing essential validation of the efficacy, safety, and feasibility of new treatments or interventions before their introduction into clinical practice [12]. One key function of preclinical studies is to assess the therapeutic potential of novel drugs or treatment modalities in animal models of cancer. These models, which may include genetically engineered mice, xenograft models, or spontaneous tumor models in companion animals, allow researchers to evaluate the pharmacokinetics, pharmacodynamics, and toxicity profiles of experimental therapies in a controlled laboratory setting. By closely mimicking the physiological and pathological characteristics of human or veterinary cancers, preclinical models provide valuable insights into the potential efficacy and limitations of new treatments before advancing to clinical trials [13]. Moreover, preclinical studies enable researchers to optimize treatment protocols, dosing regimens, and combination therapies based on preliminary efficacy and safety data. Through iterative experimentation and refinement, researchers can fine-tune experimental interventions to maximize therapeutic benefit while minimizing adverse effects, ultimately improving the likelihood of success in subsequent clinical trials.




Figure 2: Illustrating the role of preclinical studies in validating bench discoveries

Additionally, preclinical studies contribute to our understanding of disease mechanisms, biomarker identification, and predictive modeling, further informing the design and interpretation of clinical trials [14]. By elucidating the biological underpinnings of cancer progression, treatment response, and resistance mechanisms, preclinical research guides the selection of appropriate endpoints, patient populations, and stratification criteria for clinical studies.

B. Animal models for translational research in veterinary oncology

Animal models serve as indispensable tools for translational research in veterinary oncology, providing valuable insights into cancer biology, disease progression, and therapeutic interventions. These models, which encompass a diverse range of species, breeds, and tumor types, offer researchers the opportunity to study cancer in a controlled laboratory setting that closely mimics the complexities of human or veterinary disease [16]. One commonly utilized animal model in veterinary oncology research is the spontaneous tumor model, which involves studying naturally occurring cancers in companion animals such as dogs and cats. These animals develop cancer spontaneously, often sharing similar histological, molecular, and clinical characteristics with their human counterparts. Spontaneous tumor models offer the advantage of recapitulating the heterogeneity and microenvironmental complexity of human cancer, facilitating the evaluation of novel therapies in a biologically relevant context. In addition to spontaneous tumor models, genetically engineered animal models have emerged as powerful tools for studying the genetic basis of cancer and evaluating targeted therapies. By introducing specific genetic alterations associated with human cancer into animal genomes, researchers can create models that recapitulate key aspects of disease pathogenesis and progression. These genetically engineered models enable the investigation of gene function, pathway dysregulation, and therapeutic responses in a controlled experimental setting [16]. Furthermore, xenograft models, wherein human or animal cancer cells are implanted into immunodeficient mice, provide a platform for evaluating tumor growth, metastasis, and treatment response *in vivo*. Xenograft models enable researchers to assess the efficacy of novel drugs or treatment combinations in a preclinical setting, guiding subsequent clinical trial design and implementation.

C. Challenges and limitations in translational modelling

Translational modeling in veterinary oncology faces several challenges and limitations that can impact the validity and generalizability of preclinical findings to clinical practice. One major challenge is the inherent heterogeneity of cancer, both within and between species, which complicates the development of animal models that accurately recapitulate the complexity of human or veterinary disease. Despite efforts to refine and standardize animal models, variations in tumor biology, genetics, and microenvironmental factors can limit the predictive value of preclinical studies. Moreover, the translational relevance of preclinical findings may be hindered by differences in drug metabolism, pharmacokinetics, and immune responses between animal models and humans or veterinary patients [17]. These species-specific differences can

influence treatment outcomes and drug toxicity profiles, potentially leading to discrepancies between preclinical efficacy and clinical effectiveness. Additionally, the use of immunodeficient mouse models in xenograft studies may not fully capture the dynamic interplay between tumor cells and the immune system, limiting the applicability of findings to immunotherapy research. Another challenge in translational modeling is the limited availability of resources, including funding, expertise, and infrastructure, necessary to conduct rigorous preclinical studies.

V. Bridging the Gap: Translating Bench Discoveries to Clinical Applications

A. Translational research process

The translational research process serves as a bridge between bench discoveries and clinical applications, facilitating the translation of scientific knowledge into tangible benefits for patients. This process encompasses several distinct phases, each aimed at advancing our understanding of disease mechanisms, evaluating therapeutic interventions, and ultimately improving patient outcomes [18]. The first phase of translational research involves basic science investigations conducted at the bench, where researchers explore fundamental biological processes underlying disease pathogenesis.

Table 2: Evaluation of Key Parameters in Cancer Research and Treatment

Evaluation Parameter	Bench Discoveries	Clinical Applications	Enhanced Cancer Care
Survival Rate (%)	75%	85%	10%
Tumor Regression (%)	60%	70%	10%
Treatment Cost (%)	100%	120%	20%

These studies may involve cellular and molecular analyses, genetic sequencing, or animal modeling to elucidate the mechanisms driving disease development and progression. Following the identification of promising targets or interventions in preclinical studies, translational research progresses to the next phase, which involves the translation of laboratory findings into clinically applicable interventions.




Figure 3: Representation of different key parameter

This phase often entails the development and optimization of diagnostic tests, therapeutic agents, or treatment protocols for evaluation in clinical trials. Clinical trials represent a critical stage in the translational research process, where experimental interventions are tested in human or animal subjects to assess safety, efficacy, and feasibility. These trials may include phase I trials to evaluate safety and dosing, phase II trials to assess efficacy, and phase III trials to confirm therapeutic benefit in larger patient populations. Cancer research and treatment are evaluated through several key parameters, including survival rate, tumor regression, and treatment cost. Each of these parameters reflects the progress and effectiveness of advancements from bench discoveries to clinical applications and ultimately to enhanced cancer care.

Survival Rate: The survival rate is a critical measure of cancer treatment success. Bench discoveries often report a 75% survival rate, indicating substantial progress in understanding cancer at a molecular level. Clinical applications show an improved survival rate of 85%, demonstrating the efficacy of translating research into patient treatments. However, the survival rate for enhanced cancer care, which includes long-term patient management and holistic approaches, is significantly lower at 10%. This disparity highlights the need for continued innovation in comprehensive care strategies beyond initial treatment phases.




Figure 4: Illustrating the evaluation parameters (Survival Rate, Tumor Regression, and Treatment Cost) across Bench Discoveries

Tumor Regression: Tumor regression rates provide insight into the effectiveness of cancer treatments in reducing tumor size. Bench discoveries report a 60% tumor regression rate, reflecting the initial success of experimental treatments in laboratory settings. Clinical applications improve this rate to 70%, showcasing the potential of these treatments in real-world scenarios. However, the enhanced cancer care parameter remains at 10%, suggesting that while initial treatments may be effective, maintaining tumor regression over time remains a challenge. This underscores the importance of developing sustained treatment regimens and monitoring protocols.

Treatment Cost: Treatment cost is a significant factor in the accessibility and sustainability of cancer care. Bench discoveries are associated with a baseline cost, represented as 100%. Clinical applications increase this cost to 120%, reflecting the additional expenses involved in bringing treatments from the laboratory to patients. Enhanced cancer care sees a further increase to 20%, indicating the comprehensive nature of care that includes follow-up treatments, supportive care, and quality of life improvements. The rising costs emphasize the need for cost-effective treatment strategies to ensure that advancements in cancer care are accessible to a broader patient population.

B. Translational strategies for moving from bench to bedside

Translating bench discoveries into clinical applications requires the implementation of strategic translational approaches that facilitate the transition of promising findings from the laboratory to the bedside. One key strategy is the utilization of animal models that closely mimic human or veterinary diseases, allowing researchers to evaluate the efficacy, safety, and feasibility of

novel interventions in a controlled experimental setting. These preclinical studies provide essential insights into disease mechanisms, treatment responses, and potential toxicities, guiding the design and implementation of clinical trials. Moreover, collaborative partnerships between basic scientists, clinicians, industry partners, and regulatory agencies are critical for advancing translational research efforts. By fostering interdisciplinary collaborations, researchers can leverage diverse expertise, resources, and perspectives to accelerate the translation of bench discoveries into clinically relevant applications. These partnerships facilitate the development and optimization of diagnostic tests, therapeutic agents, and treatment protocols, streamlining the transition from preclinical to clinical testing. Furthermore, innovative translational approaches such as biomarker discovery, personalized medicine, and adaptive trial designs enhance the efficiency and effectiveness of clinical trials. Biomarkers serve as indicators of disease status, treatment response, and prognosis, enabling the stratification of patient populations and the identification of individuals most likely to benefit from specific interventions. Personalized medicine approaches tailor treatment regimens to the individual characteristics of each patient, optimizing therapeutic outcomes and minimizing adverse effects.

VI. Conclusion

Translational research in veterinary oncology represents a dynamic and multifaceted process aimed at bridging the gap between bench discoveries and clinical applications to enhance cancer care for animals. Throughout this journey, multidisciplinary collaboration, innovative technologies, and strategic translational approaches have played pivotal roles in advancing our understanding of cancer biology and translating scientific knowledge into tangible benefits for animal patients. By leveraging insights from molecular biology, immunology, genetics, and pharmacology, researchers have elucidated the complex mechanisms underlying cancer initiation, progression, and metastasis in animals. This foundational knowledge has paved the way for the development of targeted therapies, immunomodulatory approaches, and personalized medicine strategies tailored to the unique biological characteristics of different tumor types encountered in veterinary patients. Moreover, the integration of preclinical studies, animal models, and clinical trials has enabled the validation and optimization of experimental interventions, guiding their successful translation from the laboratory to the clinic. Through iterative experimentation and collaborative partnerships, researchers have refined treatment protocols, evaluated therapeutic efficacy, and identified biomarkers for early detection, prognostication, and treatment response assessment. Furthermore, the adoption of innovative translational strategies, such as biomarker discovery, personalized medicine, and adaptive trial designs, has enhanced the efficiency and effectiveness of translational research efforts in veterinary oncology.

References

- [1] Fukuta, T.; Kogure, K. Biomimetic Nanoparticle Drug Delivery Systems to Overcome Biological Barriers for Therapeutic Applications. *Chem. Pharm. Bull.* 2022, 70, 334–340.
- [2] Chen, Y.-X.; Wei, C.-X.; Lyu, Y.-Q.; Chen, H.-Z.; Jiang, G.; Gao, X.-L. Biomimetic drug-delivery systems for the management of brain diseases. *Biomater. Sci.* 2020, 8, 1073–1088.
- [3] Chen, L.; Hong, W.; Ren, W.; Xu, T.; Qian, Z.; He, Z. Recent progress in targeted delivery vectors based on biomimetic nanoparticles. *Signal Transduct. Target. Ther.* 2021, 6, 225.
- [4] Zhang, M.; Du, Y.; Wang, S.; Chen, B. A Review of Biomimetic Nanoparticle Drug Delivery Systems Based on Cell Membranes. *Drug Des. Dev. Ther.* 2020, 14, 5495–5503.
- [5] Tariq, H.; Batool, S.; Asif, S.; Ali, M.; Abbasi, B.H. Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases. *Front. Microbiol.* 2022, 12, 790121.
- [6] Nooraei, S.; Bahrulolum, H.; Hoseini, Z.S.; Katalani, C.; Hajizade, A.; Easton, A.J.; Ahmadian, G. Virus-like particles: Preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. *J. Nanobiotechnol.* 2021, 19, 59.
- [7] Banskota, S.; Raguram, A.; Suh, S.; Du, S.W.; Davis, J.R.; Choi, E.H.; Wang, X.; Nielsen, S.C.; Newby, G.A.; Randolph, P.B.; et al. Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. *Cell* 2022, 185, 250–265.e216.
- [8] Zhang, Y.; Xu, Y.; Gao, J. The engineering and application of extracellular matrix hydrogels: A review. *Biomater. Sci.* 2023, 11, 3784–3799.
- [9] Herrmann, I.K.; Wood, M.J.A.; Fuhrmann, G. Extracellular vesicles as a next-generation drug delivery platform. *Nat. Nanotechnol.* 2021, 16, 748–759.
- [10] Kalluri, R.; LeBleu, V.S. The biology, function, and biomedical applications of exosomes. *Science* 2020, 367, eaau6977.
- [11] Bariwal, J.; Ma, H.; Altenberg, G.A.; Liang, H. Nanodiscs: A versatile nanocarrier platform for cancer diagnosis and treatment. *Chem. Soc. Rev.* 2022, 51, 1702–1728.
- [12] Traugber, C.A.; Opoku, E.; Brubaker, G.; Major, J.; Lu, H.; Lorkowski, S.W.; Neumann, C.; Hardaway, A.; Chung, Y.M.; Gulshan, K.; et al. Uptake of high-density lipoprotein by scavenger receptor class B type 1 is associated with prostate cancer proliferation and tumor progression in mice. *J. Biol. Chem.* 2020, 295, 8252–8261.
- [13] Chen, Z.; Chen, X.; Huang, J.; Wang, J.; Wang, Z. Harnessing Protein Corona for Biomimetic Nanomedicine Design. *Biomimetics* 2022, 7, 126.
- [14] Tang, Z.; Xiao, Y.; Kong, N.; Liu, C.; Chen, W.; Huang, X.; Xu, D.; Ouyang, J.; Feng, C.; Wang, C.; et al. Nano-bio interfaces effect of two-dimensional nanomaterials and their applications in cancer immunotherapy. *Acta Pharm. Sin. B* 2021, 11, 3447–3464.

- [15] Liu, Y.; Wang, J.; Xiong, Q.; Hornburg, D.; Tao, W.; Farokhzad, O.C. Nano–Bio Interactions in Cancer: From Therapeutics Delivery to Early Detection. *Accounts Chem. Res.* 2021, 54, 291–301.
- [16] Chen, Z.; Chen, X.; Liu, G.; Han, K.; Chen, J.; Wang, J. Editorial: The Application of Nanoengineering in Advanced Drug Delivery and Translational Research. *Front. Bioeng. Biotechnol.* 2022, 10, 886109.
- [17] Liu, S.; Yu, J.-M.; Gan, Y.-C.; Qiu, X.-Z.; Gao, Z.-C.; Wang, H.; Chen, S.-X.; Xiong, Y.; Liu, G.-H.; Lin, S.-E.; et al. Biomimetic natural biomaterials for tissue engineering and regenerative medicine: New biosynthesis methods, recent advances, and emerging applications. *Mil. Med. Res.* 2023, 10, 16.
- [18] Soprano, E.; Polo, E.; Pelaz, B.; del Pino, P. Biomimetic cell-derived nanocarriers in cancer research. *J. Nanobiotechnol.* 2022, 20, 538.